Table 1.
Valid Cases | N (%) | |
---|---|---|
No of patients | 22 | |
Male:Female | 11 : 11 | 50 : 50 |
Median Age, y, (Range) | 65 (35-77) | |
Performance Status WHO | ||
0, 1, 2, 3, 4 | 6 / 10 / 3 / 2 / 1 | 27.0 / 45.5 / 14.0 / 9.0 / 4.5 |
Primary Tumor | ||
Pancreas | 2 | 9 |
Esophagus/Cardia | 8 | 36 |
Small Intestine | 2 | 9 |
Colon | 1 | 5 |
CUP (Cancer of unknown primary) | 9 | 41 |
Chromogranin A Immunohistochemistry | ||
Strongly positive / Positive/ Weakly positive/ Negative / Not Done | 4 / 8 / 7 / 1 / 2 | 18 / 36 / 32 / 5 / 9 |
Synaptophysin Immunohistochemistry | ||
Strongly positive / Positive/ Weakly positive/ Negative | 11 / 9 / 1 / 1 | 50 .0 / 41.0 / 4.5 / 4.5 |
Somatostatin Receptor Scintigraphy | ||
Strongly positive (>liver uptake) | 3 | 14.5 |
Weakly Positive (<liver uptake) | 3 | 14.5 |
Negative | 10 | 46.0 |
Not done | 6 | 27.0 |
Ki-67 | ||
Median, %, (Range) | 95 (25-100) | |
≥ 55% | 17 | 77 |
< 55% | 5 | 23 |
Site of metastases | ||
Liver | 11 | |
Lymph nodes | 19 | |
Brain | 3 | |
Bone | 5 | |
Pleural | 1 | |
Lung | 3 | |
Skin | 2 | |
Breast | 1 | |
Peritoneal, Retroperitoneal | 4 | |
No. of metastatic sites | ||
1 | 7 | 32 |
2 | 7 | 32 |
≥3 | 8 | 36 |